STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
AdComrejectedNegative
AI Analysis
Summary
An FDA advisory panel rejected a Capricor treatment for Duchenne muscular dystrophy, concluding that clinical data did not provide substantial evidence of efficacy.
Outcome Details
FDA advisory panel concluded clinical data did not provide substantial evidence of efficacy
Importance:8/10
Sentiment:
-0.90
FDAadvisory panelDuchenne muscular dystrophyefficacy concernsnegative regulatory outcome
Read the original article
Published by STAT News on July 30, 2026 1:08 PM